[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Kessler M, Kandel-Tschiederer B, Pfleghaar S, Tassani-Prell M: Primary malignant lymphoma of the urinary bladder in a dog: longterm remission following treatment with radiation and chemotherapy. Schweiz Arch Tierheilkd; 2008 Nov;150(11):565-9
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant lymphoma of the urinary bladder in a dog: longterm remission following treatment with radiation and chemotherapy.
  • Primary (extranodal) malignant lymphoma limited exclusively to the urinary bladder is an extremely rare disorder in both humans and animals and has to be differentiated from malignant lymphoma cases where a systemic (multicentric) lymphoma has spread to the bladder.
  • We report a case of a 3-year old female spayed mixed breed dog presenting with gross haematuria and dysuria and diagnosed with a primary B-cell high-grade lymphoma of the urinary bladder without involvement of any other site.
  • After treatment with a combination of hypofractionated external beam radiation and cytotoxic chemotherapy, rapid and complete remission of the tumor occurred.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dog Diseases / drug therapy. Dog Diseases / radiotherapy. Lymphoma / veterinary. Urinary Bladder Neoplasms / veterinary
  • [MeSH-minor] Animals. Dogs. Female. Immunohistochemistry / veterinary. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18979422.001).
  • [ISSN] 0036-7281
  • [Journal-full-title] Schweizer Archiv für Tierheilkunde
  • [ISO-abbreviation] Schweiz. Arch. Tierheilkd.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


2. Yokoyama M, Kobayashi T, Kubo Y, Kageyama Y, Kihara K: [A case of secondary malignant lymphoma of the urinary bladder]. Hinyokika Kiyo; 2006 Apr;52(4):285-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of secondary malignant lymphoma of the urinary bladder].
  • A 56-year-old man was admitted to our hospital for salvage chemotherapy of recurrent diffuse large B cell malignant lymphoma at clinical stage IIIb and which had been treated with 6 cycles of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP).
  • Computed tomography showed multiple tumors in the bladder after a cycle of ifosfamide, etoposide and mitoxantrone (MINE), but cystoscopy after the second cycle revealed a single non-papillary tumor about 1cm in diameter.
  • After 3 cycles of MINE therapy, transurethral resection of bladder tumor was performed.
  • At the time of the operation, the protruded lesion disappeared and there remained only a scar.
  • Biopsy of the scar revealed malignant lymphoma infiltrated into the submucosal layer.
  • Although the rate of the bladder involvement of malignant lymphoma reaches 3-20% in autopsy cases, it is very rare for a secondary malignant lymphoma of the urinary bladder to be diagnosed clinically.
  • The prognosis of the secondary bladder lymphoma is much poorer than that of the primary one, because of the widespread dissemination of the disease at the time of diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Mesna / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Prednisone / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686357.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; CHOP protocol; MINE protocol
  •  go-up   go-down


3. Koike H, Morita T, Tamura Y: [Primary malignant lymphoma of the urinary bladder: a case report]. Nihon Hinyokika Gakkai Zasshi; 2004 May;95(4):675-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant lymphoma of the urinary bladder: a case report].
  • We report a case of primary malignant lymphoma of the urinary bladder.
  • Macrohematuria appeared, and the submucosal tumor was observed by cystoscopy, and A Transurethral bladder biopsy led to a histopathological diagnosis of non-Hodgkin's malignant lymphoma (diffuse lymphoma, large-sized cell type, B-cell type).
  • Clinical stage was IE, but as soon, she was get bilateral hydronephrosis and bladder-ileum fistula.
  • The administration of 6-course CHOP chemotherapy had an excellent effect of disappearing the tumor, bilateral hydronephrosis, and bladder-ileum fistula.
  • [MeSH-major] Lymphoma, B-Cell. Lymphoma, Large B-Cell, Diffuse. Urinary Bladder Neoplasms
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Prednisone / administration & dosage. Remission Induction. Stents. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15198002.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


Advertisement
4. Okumura K, Kato K, Furuhashi K, Suzuki K, Murase T: [A collision cancer between urothelial carcinoma and malignant lymphoma of the urinary bladder: a case report]. Hinyokika Kiyo; 2007 Sep;53(9):649-51
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A collision cancer between urothelial carcinoma and malignant lymphoma of the urinary bladder: a case report].
  • Abdominal computed tomography showed a low-density area in the liver and swelling of lymph nodes surrounding the abdominal aorta.
  • Four months later, he was hospitalized on an emergency basis in a urology ward in order to control bladder tamponade.
  • Cystoscopy revealed massive blood clots and a papillary tumor at the left wall of the urinary bladder.
  • He underwent transurethral resection of a bladder tumor, and the pathological diagnosis was a collision tumor between urothelial carcinoma (G2, pTa) and malignant lymphoma (B cell type).
  • He underwent a liver biopsy soon thereafter, and the pathological diagnosis was malignant lymphoma (as for the one found in the urinary bladder).
  • Bladder tamponade was repeated, which was relieved after one course of chemotherapy for malignant lymphoma.
  • He underwent six courses of chemotherapy (THP-CO), and he was well without recurrence of either malignant lymphoma or urothelial carcinoma with 3 years' follow-up.
  • [MeSH-major] Carcinoma / pathology. Lymphoma, B-Cell / pathology. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933143.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Peyromaure M, Van Glabeke E, Leblond V, Barrou B, Delcourt A, Richard F: [Primary lymphoma of the bladder]. Prog Urol; 2000 Dec;10(6):1208-11
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary lymphoma of the bladder].
  • The authors report two cases of primary non-Hodgkin's malignant lymphoma of the bladder.
  • In contra with secondary site, which are not rare, primary malignant lymphomas of the bladder wall are exceptional.
  • These tumours cannot be distinguished from other bladder tumours on the basis of their radiological or endoscopic appearance.
  • Only histology provides the diagnosis.
  • Treatment is mainly based on chemotherapy.
  • [MeSH-major] Lymphoma / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11217561.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Fujimura M, Chin K, Sekita N, Kajimoto S, Kamijima S, Suzuki H, Ichikawa T, Mikami K: [Regression of mucosa-associated lymphoid tissue lymphoma of the bladder after antibiotic therapy: a case report]. Hinyokika Kiyo; 2008 Dec;54(12):783-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regression of mucosa-associated lymphoid tissue lymphoma of the bladder after antibiotic therapy: a case report].
  • Transurethral coagulation and a biopsy of the urinary bladder were performed.
  • Histopathological examination of the biopsy revealed non-Hodgkin's lymphoma of the mucosa-associated lymphoid tissue (MALT) type.
  • Results of a computed tomography scan and gallium scintigraphy suggested that it was a primary malignant lymphoma of the urinary bladder.
  • Because of the detection of a Helicobacter pylori (HP) infection in the gastric mucosal biopsy specimens, the patient was subsequently administered HP eradication therapy.
  • Consequently, the lymphoma disappeared and the woman has had no tumor recurrence for the past 25 months.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Amoxicillin / therapeutic use. Cefoperazone / therapeutic use. Cephalosporins / therapeutic use. Clarithromycin / therapeutic use. Female. Helicobacter Infections / drug therapy. Humans. Sulbactam / therapeutic use

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. Clarithromycin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19175002.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Cephalosporins; 5J77167P9E / cefcapene pivoxil hydrochloride; 7U75I1278D / Cefoperazone; 804826J2HU / Amoxicillin; H1250JIK0A / Clarithromycin; S4TF6I2330 / Sulbactam
  •  go-up   go-down


7. Shiga Y, Suzuki K, Tsutsumi M, Ishikawa S: Transitional cell carcinoma of the renal pelvis in a patient with cyclophosphamide therapy for malignant lymphoma: a case report and literature review. Hinyokika Kiyo; 2002 May;48(5):301-5
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the renal pelvis in a patient with cyclophosphamide therapy for malignant lymphoma: a case report and literature review.
  • Cyclophosphamide is considered to be a bladder carcinogen and there are many reports of secondary bladder cancer, while only a few cases of upper urothelial cancer have been described.
  • A 59-year-old man, who had received cyclophosphamide therapy for malignant lymphoma, was suffering from gross hematuria and consulted our institute.
  • Computerized tomography (CT), intravenous pyelography (IVP) and retrograde pyelography (RP) revealed a left renal pelvic tumor.
  • Histopathological diagnosis of the left renal pelvic tumor was transitional cell carcinoma, invading the renal parenchyma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Carcinoma, Transitional Cell / chemically induced. Cyclophosphamide / adverse effects. Kidney Neoplasms / chemically induced. Lymphoma / drug therapy. Neoplasms, Second Primary / chemically induced


8. Kinouchi T, Kinoshita T, Kobayashi M, Ueda T, Inoue H, Takada T, Hara T: [A case of primary malignant lymphoma of the prostate presenting as urinary retention]. Hinyokika Kiyo; 2010 Oct;56(10):589-92
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary malignant lymphoma of the prostate presenting as urinary retention].
  • We report a case of primary malignant lymphoma of the prostate.
  • Magnetic resonance imaging showed a large mass below the bladder and in front of the rectum.
  • Histological and immunocytochemical studies of transperineal biopsy of the prostate showed diffuse large B-cell non-Hogkin's lymphoma.
  • Although the tumor was markedly reduced in size after four cycles of combination chemotherapy with cyclophosphamide, adriamycin, vincristine, and prednisolone, he died with brain metastasis 4 months after the diagnosis.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / complications. Prostatic Neoplasms / complications. Urinary Retention / etiology
  • [MeSH-minor] Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21063166.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


9. Painemal Duarte C, Gallardo J, Valdebenito JP, Gamargo C, Rubio B, Harbst H: [MALT lymphoma of the bladder. Report of a case]. Arch Esp Urol; 2001 Dec;54(10):1138-40
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MALT lymphoma of the bladder. Report of a case].
  • OBJECTIVE: To describe and discuss primary malignant lymphoreticular proliferative tumors of the bladder.
  • RESULTS: Pelvic ultrasound examination showed an 8 x 7 x 8 cm solid and cystic mass adjacent to the bladder and uterus.
  • Cystoscopic biopsy disclosed a low grade B cell non-Hodgkin lymphoma.
  • Disappearance of the mass was achieved with 6 cycles of chemotherapy and radiotherapy.
  • CONCLUSIONS: Primary malignant lymphoma of the bladder is uncommon.
  • The anatomopathological study is essential to differential diagnosis from other diseases.
  • The response to chemotherapy and radiotherapy are excellent and permits bladder preservation.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / drug therapy. Urinary Bladder Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11852527.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


10. Cantú de León D, Pérez Montiel D, Chanona Vilchis J: Primary malignant lymphoma of uterine cervix. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):923-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant lymphoma of uterine cervix.
  • Primary malignant lymphoma of the uterine cervix is a rare disease.
  • Malignant lymphoma can be clinically and histopathologically misdiagnosed for the infrequent presentation in this are.
  • A biopsy was performed and histopathological studies reported a large cell B lymphoma.
  • After the diagnosis CT abdominal, pelvic and thoracic scan was performed and shows infiltration to posterior bladder without evidence of disease in lymph nodes or another organ.
  • The patient was treated with chemotherapy and radiotherapy.
  • Six month after finish the treatment is well and free of disease.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681788.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Hiramoto K, Kuroki M, Shoji H, Matsumura Y, Miura A, Kikuchi Y, Hirakawa H, Kimura J, Matsuda M: [A case of primary hepato-biliary malignant lymphoma effectively treated with R-CHOP chemotherapy]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1345-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary hepato-biliary malignant lymphoma effectively treated with R-CHOP chemotherapy].
  • A 65-year-old man was admitted to our hospital because of obstructive jaundice caused by a mass extending in the porta hepatis, neck of gall bladder and extrahepatic bile duct.
  • The specimens obtained with ultrasound-guided needle biopsy showed malignant lymphoma (diffuse large B-cell lymphoma: DLBCL).
  • CHOP with Rituximab therapy (R-CHOP therapy) was performed.
  • The treatment resulted in remarkable reduction of the tumor size and improvement of the biliary stenosis.
  • We should take into consideration malignant lymphoma when we see a patient with a tumor of the hepato-biliary system.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Biopsy, Needle. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Humans. Magnetic Resonance Imaging. Male. Prednisone / administration & dosage. Prednisone / therapeutic use. Rituximab. Tomography, X-Ray Computed. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647724.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Gómez-Román JJ, Cobo ML, Val-Bernal JF: Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting as a bladder neoplasm. Pathol Int; 2008 Apr;58(4):249-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting as a bladder neoplasm.
  • Malignant lymphoma presenting in the bladder has been classified in primary cases, as the first sign of disseminated disease and as a secondary infiltration.
  • Reported herein is the case of a 45-year-old man with an anaplastic large cell lymphoma (anaplastic lymphoma kinase (ALK) and granzyme B positive) that presented as a bladder neoplasm.
  • The morphological differential diagnosis was complex because the EMA-positive immunophenotype, CD45 and CD3 negativity and the clinical manifestation simulated a transitional cell carcinoma.
  • It is important to be aware of its existence because a poorly differentiated bladder carcinoma cannot be ruled out if CD30 and ALK immunostaining are not performed.
  • Although bladder involvement by recurrent lymphoma is a sign of widely disseminated disease and it is associated with a very poor prognosis, it seems that chemotherapeutic regimens in this kind of ALK-positive lymphoma could be effective, given that the present patient had an impressive response to chemotherapy treatment.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Protein-Tyrosine Kinases / metabolism. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Antigens, CD30 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Diagnosis, Differential. Disease-Free Survival. Etoposide / administration & dosage. Humans. Male. Methylprednisolone / administration & dosage. Middle Aged. Mucin-1 / metabolism. Receptor Protein-Tyrosine Kinases. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324919.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / Mucin-1; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


13. Xiao ZJ, Li CL: [Diagnosis and treatment of malignant bladder non-epithelial tumors]. Zhonghua Yi Xue Za Zhi; 2008 Nov 4;88(40):2845-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of malignant bladder non-epithelial tumors].
  • OBJECTIVE: To study the clinical diagnosis, treatment, and prognosis of malignant bladder non-epithelial tumors.
  • METHODS: The clinical data of 17 cases with malignant bladder non-epithelial tumor, 15 males and 3 females, aged 28 (3-73), were analyzed.
  • RESULTS: Ten of the 17 cases were diagnosed as with rhabdomyosarcoma, 2 with malignant lymphoma, and 2 with malignant pheochromocytoma, 2 with leiomyosarcoma, and 1 with carcinosarcoma.
  • All patients underwent operation, or were treated with radiotherapy or chemotherapy.
  • Two patients with malignant lymphoma underwent partial cystectomy and adjuvant radiotherapy or chemotherapy, and survived for more than 3 years.
  • Of the 2 cases with malignant pheochromocytoma, one underwent lymphadenectomy and adjuvant chemotherapy and survived for more than 5 years; and another case died 2 years after operation and chemotherapy.
  • One case with carcinosarcoma receiving operation followed by chemotherapy died in one year.
  • CONCLUSION: Malignant bladder non-epithelial tumors are rare clinically and most of them occur in children.
  • The prognosis of malignant bladder non-epithelial tumors, different in pathological types, is relatively worse in adults.
  • [MeSH-major] Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080495.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Rabii R, Mezzour MH, Guessous H, Essaki H, Joual A, Rachid M, Quessar A, Benchekroun S, El Mrini M: [Urogenital lymphoma presenting with obstructive anuria]. Prog Urol; 2004 Feb;14(1):73-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urogenital lymphoma presenting with obstructive anuria].
  • The authors report a case of urogenital lymphoma with multiple sites in a patient presenting with oligo-anuria.
  • After a haemodialysis session and ultrasound-guided right percutaneous nephrostomy, pelvic magnetic resonance imaging (MRI) showed a very large pelvic mass between the bladder and the rectum and transrectal biopsy of the mass confirmed the diagnosis of high-grade malignant non-Hodgkin's lymphoma (NHL) with a type B lymphoblastic phenotype.
  • Treatment consisted of chemotherapy according to the LMB 93 protocol.
  • In the light of this case and a review of the literature, the authors discuss the diagnostic, therapeutic and prognostic aspects of this rare site of lymphoma.
  • [MeSH-major] Anuria / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Urogenital Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15098759.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 15
  •  go-up   go-down


15. Xu AX, Wang XX, Hong BF, Ye LY, Zhang L: [Non-epithelial tissue tumors of the urinary bladder]. Zhonghua Wai Ke Za Zhi; 2003 Jul;41(7):530-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-epithelial tissue tumors of the urinary bladder].
  • OBJECTIVE: To summarize the experience in the diagnosis and treatment of non-epithelial tissue tumor of urinary bladder.
  • METHODS: >From 1953 to April 2002, a total of 28 patients with non-epithelial tissue tumor in 3 925 bladder tumor cases were analyzed.
  • RESULTS: Painless gross hematuria, pelvic mass, urinary frequency and dysuria are symptoms of non-epithelial bladder tumor.
  • Ultrasonic examination, computed tomography (CT) scan, cystoscopy and biopsy is used for diagnosis of the tumor.
  • Seventeen of 28 patients (61.7%) were malignant neoplasms in 7 kinds of pathologic types, which was small cell carcinoma (5 cases), rhabdomyosarcoma (4 cases), leiomyosarcoma (4 cases), lymphoma (1 case), malignant fibrous histiocytoma (1 case), liposarcoma(1 case), melanoma (1 case) respectively.
  • Eleven of 28 patients (39.3%) were benign tumors with 4 kinds of histologic types including 2 cases of cavernous hemangioma, 1 case of fibroma, 1 case of leiomyoma, 7 cases of pheochromocytoma.
  • All benign tumor patients were treated with partial cystectomy, transurethral bladder tumor resect (TURBT) and fulguration.
  • In 17 malignant neoplasms patients, 7 of them received partial cystectomy, 9 received radical cystectomy, and 1 patient's tumor was unresectable.
  • Those malignant bladder tumor patient are followed up, but 3 years survival rates is only 8/17.
  • CONCLUSIONS: Non-epithelial tissue tumor of the urinary bladder is rare with complicated pathologic types.
  • Malignant neoplasms are more than benign tumors with very poor prognosis, benign tumors' prognosis is good.
  • Diagnosis rate which was confirmed before operation is low.
  • Dip biopsy under cystoscopy may enhance the diagnosis rate.
  • Surgical treatment is the main therapy for non-epithelial tissue tumor of the urinary bladder.
  • Because of the aggressive biologic behavior of malignant tumors, they should be identified promptly and treated appropriately.
  • According to the histologic appearance radiotherapy and chemotherapy is mandatory in some cases.
  • [MeSH-major] Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cystectomy / methods. Cystoscopy. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Urinary Bladder / pathology. Urinary Bladder / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12921662.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Seifart C, Seifart U, Neubauer A: [Paraparesis and sensory spinal cord transection caused by an NK-cell lymphoma]. Dtsch Med Wochenschr; 2002 May 17;127(20):1072-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paraparesis and sensory spinal cord transection caused by an NK-cell lymphoma].
  • Within 2 days a paraparesis of the legs and a bladder-colon disorder had developed.
  • Electrophysiological tests indicated a symmetrical prolonged central motor conduction time.
  • Histological findings of a biopsy from this site were suspicious of NK-cell lymphoma.
  • DIAGNOSIS, TREATMENT AND COURSE: The neurological symptoms briefly responded to glucocorticoids, but were resistant to chemotherapy.
  • Plasmapheresis, undertaken on the tentative diagnosis of paraneoplastic protein secretion, brought definite improvement in the overall condition.
  • A highly malignant lymphoma was diagnosed 12 months later.
  • It, too, proved to be treatment-refractory.
  • CONCLUSION: A cerebrospinal tap should be routinely performed in patients with NK-cell lymphoma.
  • In view of the poor prognosis, early escalation of treatment should be considered.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma / diagnosis. Paranasal Sinuses / pathology. Paraparesis / etiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Electric Conductivity. Fatal Outcome. Glucocorticoids / therapeutic use. Humans. Magnetic Resonance Imaging. Male. Plasmapheresis. Prednisolone / therapeutic use

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12016554.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glucocorticoids; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


17. Landgren O, Pfeiffer RM, Stewart L, Gridley G, Mellemkjaer L, Hemminki K, Goldin LR, Travis LB: Risk of second malignant neoplasms among lymphoma patients with a family history of cancer. Int J Cancer; 2007 Mar 1;120(5):1099-102
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of second malignant neoplasms among lymphoma patients with a family history of cancer.
  • Radiotherapy and chemotherapy are known risk factors for second cancers after lymphoma.
  • We assessed risk of second cancers associated with family history of any cancer in 41,181 patients with Hodgkin lymphoma (HL) (n = 7,476), non-Hodgkin lymphoma (NHL) (n = 25,941), or chronic lymphocytic leukemia (CLL) (n = 7,764), using a large population-based database.
  • Family history of cancer was based on a diagnosis of any cancer in 110,862 first-degree relatives.
  • Among CLL patients with positive (vs. negative) family history of cancer, we observed elevated risks of bladder (RR = 3.53, 95% CI: 1.31-9.55) and prostate cancer (RR = 2.15, 95% CI: 1.17-3.94).
  • [MeSH-major] Hodgkin Disease / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Neoplasms, Second Primary / epidemiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17131330.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Aoyama M, Aoki T, Matsuura Y, Yamanoi T, Watanabe A, Saitou N, Honma M, Ishikawa T, Kodama N, Yamamoto T: [Dramatic but temporary improvements in a case of CNS intravascular malignant lymphomatosis]. Rinsho Shinkeigaku; 2003 Jan-Feb;43(1-2):6-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dramatic but temporary improvements in a case of CNS intravascular malignant lymphomatosis].
  • A 54-year-old man with a past history of gastric malignant lymphoma treated by the total gastrectomy and the chemotherapy, developed bilateral sudden deafness one year later.
  • Two years after the gastrectomy he became abruptly paraplegic with sensory impairments of the lower extremities and neurogenic bladder.
  • Although the imaging studies of the spinal cord were negative, the myelopathic symptoms resolved dramatically after a course of pulse dose methylprednisolone therapy.
  • However, he soon developed an abnormal behavior and mental deterioration in 3 weeks.
  • As intravascular malignant lymphomatosis (IML) was suspected because of the laboratory and MRI findings, biopsies of the skin, the bone marrow, the muscle and the lymph node were carried out, without evidence of lymphoma.
  • The patient remarkably responded to biweekly CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) therapy in terms of regaining the mental alertness and improved hearing.
  • However, the CHOP therapy was prematurely interrupted prior to completion because of infective arthritis.
  • This case was of interest because a solid gastric lymphoma appears to have transformed into the form of intravascular lymphomatosis without mass formations or leukemic changes.
  • This implies that the cerebral symptoms are not necessarily the results of typical ischemic infarction, but due to relative ischemia because of chiefly capillary-venous occlusion by lymphoma cells.
  • Therefore, the therapeutic intervention may dramatically improve the symptoms due to IML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Vascular Neoplasms / drug therapy
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820543.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshō shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Number-of-references] 20
  •  go-up   go-down


19. Mohammadianpanah M, Vasei M, Mosalaei A, Omidvari S, Ahmadloo N: Malignant spinal cord compression in cancer patients may be mimicked by a primary spinal cord tumour. Eur J Cancer Care (Engl); 2006 Dec;15(5):497-500
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant spinal cord compression in cancer patients may be mimicked by a primary spinal cord tumour.
  • Although it is quite rare, second primary neoplasms in cancer patients may present with the signs and symptoms of malignant spinal cord compression.
  • We report such a case of intramedullary ependymoma of the cervical spinal cord mimicking metatstatic recurrent lymphoma and causing cord compression.
  • A 50-year-old man developed intramedullary ependymoma of the cervical spinal cord 1.5 years following chemoradiation for Waldeyer's ring lymphoma.
  • He presented with a 2-month history of neck pain, progressive upper- and lower-extremity numbness and weakness, and bowel and bladder dysfunction.
  • The clinical and radiological findings were suggestive of malignant process.
  • The development of the intramedullary ependymoma following treating lymphoma has not been reported.
  • [MeSH-major] Ependymoma / diagnosis. Neoplasms, Second Primary / diagnosis. Spinal Cord Compression / etiology. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Cervical Vertebrae. Diagnosis, Differential. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Quadriplegia / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17177910.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 10
  •  go-up   go-down


20. Liu GH, Li HZ, Wang HJ, Mao QZ, Xia M, Xie Y, Xue C, Wang H, Ji ZG: [Occurrence, types, and therapies of malignant tumors in recipients of renal transplantation]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Jun;31(3):288-91
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Occurrence, types, and therapies of malignant tumors in recipients of renal transplantation].
  • OBJECTIVE: To investigate the types and therapies of malignancies in renal allograft recipients.
  • METHODS: We retrospectively analyzed the occurrence, types, and therapies of malignancies in 498 renal allograft recipients who had received operations in Peking Union Medical College Hospital from May 1986 to October 2008.
  • RESULTS: Among 498 renal allograft recipients, 18 patients (3.6% ) were diagnosed with malignancies, which included bladder cancer (n = 5), renal pyloric cancer or ureteric cancer (n = 4), leukemia or lymphoma (n = 3), hepatic cancer (n = 2), skin cancer, rectum carcinoma, pulmonary carcinoma and thymoma (n = 1 each).
  • Three patients with bladder cancer and one patient with ureteric cancer experienced recurrences 7 to 15 months after operations; among them one bladder cancer patient died.
  • One non-Hodgkin's lymphoma patient died 11 months after chemotherapy.
  • Five cases with advanced unresectable malignancies died 8 to 17 months after the diagnosis.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621511.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Frankel SR: Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis. Semin Oncol; 2003 Apr;30(2):300-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
  • The components of the apoptotic pathway are targets for anticancer therapy.
  • Bcl-2 protein inhibits apoptosis and confers resistance to treatment with traditional cytotoxic chemotherapy, radiotherapy, and monoclonal antibodies.
  • Randomized clinical trials are currently underway to evaluate the efficacy and tolerability of oblimersen in combination with cytotoxic chemotherapy in chronic lymphocytic leukemia (CLL), multiple myeloma (MM), malignant melanoma, and non-small cell lung cancer.
  • In addition, nonrandomized trials are underway to evaluate oblimersen in non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (AML), and hormone-refractory prostate cancer.
  • Preclinical data support the clinical evaluation of oblimersen in additional tumor types, including chronic myelogenous leukemia, and breast, small cell lung, gastric, colon, bladder (CML), and Merkel cell cancers.
  • Enhancement of the efficacy of anticancer treatments with oblimersen Bcl-2 antisense therapy represents a promising new apoptosis-modulating strategy, and ongoing clinical trials will test this therapeutic approach.
  • [MeSH-major] Apoptosis. Down-Regulation / drug effects. Genes, bcl-2 / genetics. Oligonucleotides, Antisense / therapeutic use. Thionucleotides / therapeutic use. Waldenstrom Macroglobulinemia / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12720157.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / Thionucleotides; 85J5ZP6YSL / oblimersen
  • [Number-of-references] 45
  •  go-up   go-down


22. Klasa RJ, Gillum AM, Klem RE, Frankel SR: Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev; 2002 Jun;12(3):193-213
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
  • The components of the apoptotic program are targets for anticancer therapy.
  • Bcl-2 protein inhibits apoptosis and confers resistance to treatment with traditional cytotoxic chemotherapy, radiotherapy, and monoclonal antibodies (mAb).
  • Randomized clinical trials are currently underway to evaluate the efficacy and tolerability of oblimersen in combination with cytotoxic chemotherapy in chronic lymphocytic leukemia, multiple myeloma, malignant melanoma, and non-small cell lung cancer.
  • In addition, nonrandomized trials are under way to evaluate oblimersen in non-Hodgkin's lymphoma, acute myeloid leukemia, and hormone-refractory prostate cancer.
  • Preclinical data also support the clinical evaluation of oblimersen in additional tumor types, including chronic myelogenous leukemia and breast, small cell lung, gastric, colon, bladder, and Merkel cell cancers.
  • Enhancement of the efficacy of anticancer treatments with oblimersen Bcl-2 antisense therapy represents a promising new apoptosis-modulating strategy, and ongoing clinical trials will test this therapeutic approach.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Oligonucleotides, Antisense / pharmacology. Proto-Oncogene Proteins c-bcl-2 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12162702.001).
  • [ISSN] 1087-2906
  • [Journal-full-title] Antisense & nucleic acid drug development
  • [ISO-abbreviation] Antisense Nucleic Acid Drug Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger
  • [Number-of-references] 124
  •  go-up   go-down


23. Bhargava P, Zhuang H, Kumar R, Charron M, Alavi A: Iatrogenic artifacts on whole-body F-18 FDG PET imaging. Clin Nucl Med; 2004 Jul;29(7):429-39

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of these, 9 patients had lymphoma, 7 had colon cancer, 6 had lung cancer, 3 had lung nodules, 2 each had breast and bladder cancer, and 1 patient had brain cancer.
  • All patients had a history of some surgical or medical intervention for malignant or some other associated disease.
  • Six patients had artifacts from previous surgery, 3 from previous radiation therapy, 3 from previous chemotherapy, and 1 from changes in glucose metabolism.
  • [MeSH-major] Artifacts. Fluorodeoxyglucose F18. Radiopharmaceuticals. Tomography, Emission-Computed. Whole-Body Counting
  • [MeSH-minor] Adult. Breast Neoplasms / radionuclide imaging. Catheterization / instrumentation. Catheters, Indwelling. Colonic Neoplasms / radionuclide imaging. Female. Humans. Image Processing, Computer-Assisted. Intubation / instrumentation. Lung Neoplasms / radionuclide imaging. Lymphoma / radionuclide imaging. Male. Middle Aged. Ostomy. Prostheses and Implants

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15192468.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


24. Hassan HT: Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy. Leuk Res; 2004 Jul;28(7):667-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy.
  • Several garlic compounds including allicin and its corresponding sulfide inhibit the proliferation and induce apoptosis of several human non-leukaemia malignant cells including breast, bladder, colorectal, hepatic, prostate cancer, lymphoma and skin tumour cell lines.
  • More significantly, ajoene profoundly enhanced the apoptotic effect of the two chemotherapeutic drugs: cytarabine and fludarabine in human CD34-positive resistant myeloid leukaemia cells through enhancing their bcl-2 inhibitory and caspase-3 activation activities.
  • Since acute myeloid leukaemia (AML) is a heterogeneous malignant disease in which disease progression at the level of CD34-positive cells has a major impact on resistance to chemotherapy and relapse and the inability to undergo apoptosis is a crucial mechanism of multi-drug resistance in AML patients.
  • The recent findings of the potent enhancing activity of ajoene on chemotherapy-induced apoptosis in CD34-positive resistant human myeloid leukaemia cells suggest a novel promising role for the treatment of refractory and/or relapsed AML patients as well as elderly AML patients.
  • [MeSH-major] Disulfides / therapeutic use. Garlic. Leukemia, Myeloid / drug therapy. Plant Extracts / therapeutic use
  • [MeSH-minor] Acute Disease. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Drug Synergism. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15158086.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Editorial; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Disulfides; 0 / Plant Extracts; 99A0041VG8 / ajoene
  • [Number-of-references] 66
  •  go-up   go-down


25. Valdés Olmos RA, Hoefnagel CA, Bais E, Boot H, Taal B, de Kraker J, Vote PA: [Therapeutic advances of nuclear medicine in oncology]. Rev Esp Med Nucl; 2001 Dec;20(7):547-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic advances of nuclear medicine in oncology].
  • With the development of new radiopharmaceuticals there is a tendency to apply nuclear medicine therapy for malignancies of higher incidence (lymphoma, prostate) than the ones which have been treated for many years (thyroid cancer, neuroendocrine tumours).
  • One of the most important areas of current development in radionuclide cancer therapy is the monotherapeutic use of new or already available radiopharmaceuticals in preclinical or phase I studies and to a lesser degree in phase II trials.
  • In this context, the radioimmunotherapy is showing important advances in the treatment of medullary thyroid carcinoma, malignant lymphomas en brain tumours with potential extension to neuroblastoma therapy.
  • The development of DOTA as a chelating agent has lead to the use of Y-90-DOTATOC in the treatment of neuroendocrine tumours, particularly carcinoid tumours, and non-I131I-avid thyroid carcinomas.
  • In an effort to improve tumour targeting together with simultaneous reduction of physiological organ uptake, 131I-MIBG is being used in combination with interferon a and pre-targeting with unlabelled MIBG in the treatment of carcinoid tumours.
  • New routes of administration of radiopharmaceuticals (intratumoral, intra-arterial) have enhanced the treatment of malignancies of liver, pancreas and brain as well as the potential use of radioimmunotherapy by intravesical administration for bladder carcinoma.
  • Another significant tendency in radionuclide therapy is its evolution from monotherapy towards a combined application with other anticancer modalities.
  • Some recent examples of combined therapy with demonstrated anti-tumour effect are found in neuroblastoma (131I-MIBG and chemotherapy), bone metastases of prostatic carcinoma (addition of 89Sr to chemotherapy schedules), brain malignancies (adjuvant use of radioimmnunotherapy in relation to surgery and external radiotherapy) and lymphoma (radioimmunotherapy combined with chemotherapy or immunotherapy).
  • [MeSH-minor] 3-Iodobenzylguanidine / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Brain Neoplasms / radionuclide imaging. Carcinoma / radionuclide imaging. Carcinoma / secondary. Carcinoma, Medullary / radionuclide imaging. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Combined Modality Therapy. Humans. Hyperbaric Oxygenation. Iodine Radioisotopes / administration & dosage. Iodine Radioisotopes / therapeutic use. Liver Neoplasms / radionuclide imaging. Lymphoma / radionuclide imaging. Lymphoma / therapy. Neoplasms / diagnosis. Neoplasms / radiotherapy. Neoplasms / therapy. Neuroblastoma / radionuclide imaging. Neuroblastoma / radiotherapy. Radioimmunotherapy. Radiopharmaceuticals / therapeutic use. Thyroid Neoplasms / radionuclide imaging. Thyroid Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11709141.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 35MRW7B4AD / 3-Iodobenzylguanidine
  • [Number-of-references] 56
  •  go-up   go-down


26. Cheng L, Foster SR, MacLennan GT, Lopez-Beltran A, Zhang S, Montironi R: Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum? J Urol; 2008 Oct;180(4):1235-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Inflammatory myofibroblastic tumor of the genitourinary tract is a spindled soft tissue lesion that is often mistaken for sarcoma.
  • We investigated whether inflammatory myofibroblastic tumors in adults and children are the same entity, and whether inflammatory myofibroblastic tumor is part of a biological spectrum that includes benign and malignant entities at opposite ends.
  • RESULTS: The literature suggests that with evidence of anaplastic lymphoma kinase rearrangement and expression, the lesion is neoplastic rather than reactive, differentiating it from previously described lesions.
  • CONCLUSIONS: Inflammatory myofibroblastic tumor of the genitourinary tract should be considered a neoplasm of uncertain malignant potential, and routine surveillance and close clinical followup are recommended.
  • Aggressive therapy (radical cystectomy, radiation or chemotherapy) is unwarranted given the indolent and often benign clinical course for the majority of cases.
  • To understand the diagnostic and prognostic implications future emphasis should be placed on the link between genetic abnormalities, and clinical course, therapeutic response and ultimate outcome.
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Incidence. Neoplasm Staging. Prognosis. Risk Assessment. Ureteral Neoplasms / diagnosis. Ureteral Neoplasms / pathology. Urethral Neoplasms / diagnosis. Urethral Neoplasms / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707729.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


27. Pearce HL, Alice Miller M: The evolution of cancer research and drug discovery at Lilly Research Laboratories. Adv Enzyme Regul; 2005;45:229-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evolution of cancer research and drug discovery at Lilly Research Laboratories.
  • This review highlights the discovery and development of chemotherapy at Eli Lilly & Company over the past 30 years from the Vinca alkaloids-vincristine, vinblastine, and vindesine-to targeted therapy.
  • Two such agents, gemcitabine and pemetrexed, underwent clinical development and are now among Lilly's portfolio of approved anticancer drugs.
  • Gemcitabine, a pyrimidine nucleoside that has a profound effect on DNA synthesis, has been approved for the treatment of pancreatic, non-small cell lung, bladder, and most recently, breast, and ovarian cancer.
  • Pemetrexed, given in combination with cisplatin, has been recently approved for the treatment of malignant pleural mesothelioma and as second-line treatment for non-small cell lung cancer.
  • Spurred by advances in the understanding of cancer as a disease process, Lilly's anticancer drug program began to transition to a more "targeted" approach during the 1990s.
  • Enzastaurin has shown promising single-agent activity in patients with relapsed diffuse large B-cell lymphoma and recurrent glioblastoma multiforme, and is an excellent candidate for combination with cytotoxic agents.
  • [MeSH-major] Antineoplastic Agents / history. Drug Industry / history. Neoplasms / history
  • [MeSH-minor] Clinical Trials as Topic. Deoxycytidine / analogs & derivatives. Deoxycytidine / history. Deoxycytidine / pharmacology. Deoxycytidine / therapeutic use. Glutamates / history. Glutamates / pharmacology. Glutamates / therapeutic use. Guanine / analogs & derivatives. Guanine / history. Guanine / pharmacology. Guanine / therapeutic use. History, 20th Century. Humans. Indoles / history. Indoles / pharmacology. Indoles / therapeutic use. Pemetrexed. United States

  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16143373.001).
  • [ISSN] 0065-2571
  • [Journal-full-title] Advances in enzyme regulation
  • [ISO-abbreviation] Adv. Enzyme Regul.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 0 / Indoles; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine; UC96G28EQF / enzastaurin
  •  go-up   go-down


28. Várady E, Deák B, Molnár ZS, Rosta A, Schneider T, Esik O, Eckhardt S: Second malignancies after treatment for Hodgkin's disease. Leuk Lymphoma; 2001 Nov-Dec;42(6):1275-81
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies after treatment for Hodgkin's disease.
  • The occurrence of treatment-related second malignancy following Hodgkin's disease (HD) has now been recognized as a major problem.
  • Second neoplasm developed in 32 cases (4.8%).
  • Among patients with second hematological malignancies, the mean age at diagnosis of HD was 44 years and the mean interval until the development of second malignancy was 6.1 years.
  • Five patients received chemo- and radiotherapy and in two cases chemotherapy was used.
  • Twenty-five patients have had solid tumors, affecting lung (5), breast (3), colon (3), stomach (2), urinary bladder (2), head-and-neck (1), thyroid gland (1), esophagus (1), liver (1), pancreas (1), furthermore, three sarcomas and two malignant melanomas were observed.
  • Their mean age at the diagnosis of HD was 46 years and the mean period of latency was 8.3 years.
  • Chemotherapy was applied to nine patients, 16 patients received both chemo- and radiotherapy.
  • Since alkylating agents increase the risk of leukemia and irradiation contributes mainly to other malignancies, future treatment protocols should attempt to reduce the most serious consequence of therapy without compromising the survival.
  • [MeSH-major] Hodgkin Disease / therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911408.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


29. Nonomura N, Ono Y, Nozawa M, Fukui T, Harada Y, Nishimura K, Takaha N, Takahara S, Okuyama A: Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. Eur Urol; 2000 Dec;38(6):701-4;discussion 705
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract.
  • OBJECTIVES: The aim of this study is to evaluate the efficacy and safety of intrarenal bacillus Calmette-Guérin (BCG) instillation as a treatment for transitional cell carcinoma in situ (CIS) of the upper urinary tract.
  • METHODS: Diagnostic criteria of upper urinary tract CIS were (1) positive urinary cytology, (2) negative multiple random biopsy of the bladder and prostatic urethra, (3) negative radiographic findings in the upper urinary tract and (4) two serial positive cytologies in selective ipsilateral urine sampling from the pyeloureteral system.
  • After placing a 6-french Double-J stent, BCG (80 mg) in 40 ml saline was instilled into the bladder weekly, 6 times in total as one course.
  • Mean recurrence-free time was 19.6 months.
  • The other case was diagnosed as having malignant lymphoma 3 months after the end of this instillation therapy, and he died of malignant lymphoma.
  • As side effects, 8 cases (72.7%) showed bladder irritability, and 4 presented fever higher than 38 degrees C.
  • However, no patient needed antitubercular treatment.
  • CONCLUSION: As for the short-term response, BCG instillation for the treatment of upper urinary tract CIS is considered to be effective and safe.
  • Longer follow-up and further experience with this treatment are required.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Carcinoma in Situ / therapy. Carcinoma, Transitional Cell / therapy. Kidney Neoplasms / therapy. Ureteral Neoplasms / therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Disease-Free Survival. Follow-Up Studies. Humans. Instillation, Drug. Male. Perfusion. Stents. Time Factors

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11111187.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


30. Djeu JY, Wei S: Clusterin and chemoresistance. Adv Cancer Res; 2009;105:77-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Resistance to anticancer agents is one of the primary impediments to effective cancer therapy.
  • Chemoresistance occurs not only to clinically established therapeutic agents but also to novel targeted therapeutics.
  • Both intrinsic and acquired mechanisms have been implicated in drug resistance but it remains controversial which mechanisms are responsible that lead to failure of therapy in cancer patients.
  • Moreover, it is abnormally upregulated in numerous advanced stage and metastatic cancers spanning prostate, renal, bladder, breast, head and neck, colon, cervical, pancreatic, lung carcinomas, melanoma, and lymphoma.
  • Expression of sCLU may be an adaptive response to genotoxic and oxidative stresses but this adaptive response could pose a threat in malignant cells being treated with cytotoxic agents by enhancing their survival potential.
  • Thus, sCLU has a key role in preventing apoptosis induced by cytotoxic agents and has the potential to be targeted for cancer therapy.
  • [MeSH-major] Clusterin / physiology. Drug Resistance, Neoplasm. Neoplasms / drug therapy
  • [MeSH-minor] Drug Resistance, Multiple. Humans. Oxidative Stress

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2005 Jun;124(6):1300-7 [15955107.001]
  • [Cites] Nat Cell Biol. 2005 Sep;7(9):909-15 [16113678.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96 [16145049.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Mar;2(3):150-7 [16264908.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):1837-49 [16373699.001]
  • [Cites] Biochem J. 2006 Apr 1;395(1):223-31 [16336210.001]
  • [Cites] Nat Clin Pract Oncol. 2006 May;3(5):269-80 [16683005.001]
  • [Cites] Urology. 2006 Sep;68(3):609-14 [16979705.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6113-22 [16652143.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):611-22 [17096323.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2278-87 [17148459.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):9-23 [17084534.001]
  • [Cites] Histopathology. 2007 Feb;50(3):331-7 [17257128.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Apr;4(4):236-44 [17392714.001]
  • [Cites] Neoplasia. 2001 Jul-Aug;3(4):360-7 [11571636.001]
  • [Cites] Mol Urol. 2001 Autumn;5(3):105-11 [11690557.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4245-52 [11751526.001]
  • [Cites] Prostate. 2002 Feb 15;50(3):179-88 [11813210.001]
  • [Cites] Cell Stress Chaperones. 2002 Jan;7(1):23-35 [11892985.001]
  • [Cites] Urology. 2002 Sep;60(3):516-20 [12350509.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3276-84 [12374699.001]
  • [Cites] Nat Cell Biol. 2003 Apr;5(4):320-9 [12652308.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4):372-80 [14508108.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38214-9 [12882985.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1834-42 [14996747.001]
  • [Cites] Mol Cancer Ther. 2004 Mar;3(3):223-32 [15026542.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2298-304 [14755245.001]
  • [Cites] Cell Cycle. 2009 Feb 1;8(3):473-81 [19177010.001]
  • [Cites] Eur J Cancer. 2009 Jul;45(10):1846-54 [19342222.001]
  • [Cites] Int J Cancer. 2009 Aug 15;125(4):791-806 [19391138.001]
  • [Cites] Oncogene. 2009 Sep 17;28(37):3307-19 [19597465.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):170-6 [10646870.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2547-54 [10811138.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1655-63 [10815883.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5907-12 [10823943.001]
  • [Cites] Blood. 2000 Jul 15;96(2):398-404 [10887098.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21055-60 [10770937.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):393-9 [10934144.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jan;280(1):G149-56 [11123208.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3869-76 [11358798.001]
  • [Cites] Urology. 2001 Aug;58(2 Suppl 1):39-49 [11502446.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3126-36 [15126350.001]
  • [Cites] J Urol. 2004 Jun;171(6 Pt 1):2477-81 [15126879.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] Prostate. 2004 Dec 1;61(4):318-23 [15389725.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Aug 31;147(1):196-203 [3632663.001]
  • [Cites] Biochem J. 1989 Jan 1;257(1):293-6 [2920020.001]
  • [Cites] Mol Cell Biol. 1989 Aug;9(8):3473-81 [2477686.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8577-81 [1924317.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6940-4 [1458483.001]
  • [Cites] J Cancer Res Clin Oncol. 1994;120(3):186-8 [8263017.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2431-7 [7757997.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):229-33 [9000560.001]
  • [Cites] J Biol Chem. 1997 Oct 17;272(42):26620-6 [9334243.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30777-84 [9804855.001]
  • [Cites] J Biol Chem. 1998 Nov 20;273(47):31068-74 [9813006.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1596-605 [17404365.001]
  • [Cites] ChemMedChem. 2007 Jul;2(7):920-42 [17530726.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1772(9):1103-11 [17689225.001]
  • [Cites] Mol Cancer Ther. 2007 Nov;6(11):2938-47 [18025278.001]
  • [Cites] Cell Cycle. 2007 Nov 15;6(22):2782-7 [17998803.001]
  • [Cites] Kidney Int. 2008 Mar;73(5):567-77 [18075502.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):527-32 [18177691.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1291-5 [18316546.001]
  • [Cites] J Biol Chem. 2008 May 9;283(19):12851-61 [18321852.001]
  • [Cites] J Urol. 2008 Aug;180(2):565-70; discussion 570 [18554663.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):48-59 [19118032.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):403-6 [19147550.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):708-13 [19147778.001]
  • [Cites] J Cell Mol Med. 2008 Dec;12(6B):2566-85 [19210756.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1707-11 [9815554.001]
  • [Cites] Prostate. 1999 May;39(2):87-93 [10221563.001]
  • [Cites] Eur J Biochem. 1999 Jul;263(2):534-42 [10406964.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):277-83 [15578711.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95 [15663992.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):14212-21 [15689620.001]
  • [Cites] J Cell Physiol. 2005 Aug;204(2):463-9 [15685647.001]
  • (PMID = 19879424.001).
  • [ISSN] 0065-230X
  • [Journal-full-title] Advances in cancer research
  • [ISO-abbreviation] Adv. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098080
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLU protein, human; 0 / Clusterin
  • [Number-of-references] 78
  • [Other-IDs] NLM/ NIHMS539156; NLM/ PMC3889866
  •  go-up   go-down


31. Borden EC: Review: Milstein Award lecture: interferons and cancer: where from here? J Interferon Cytokine Res; 2005 Sep;25(9):511-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interferons (IFNs) remain the most broadly active cytokines for cancer treatment, yet ones for which the full potential is not reached.
  • IFNs have impacted positively on both quality and quantity of life for hundreds of thousands of cancer patients with chronic leukemia, lymphoma, bladder carcinoma, melanoma, and renal carcinoma.
  • The role of the IFN system in malignant pathogenesis continues to enhance understanding of how the IFN system may be modulated for therapeutic advantage.
  • Reaching the full potential of IFNs as therapeutics for cancer will also result from additional understanding of the genes underlying apoptosis induction, angiogenesis inhibition, and influence on immunologic function.
  • Food and Drug Administration (FDA) approval of IFNs occurred less than 20 years ago; after 40 years, third-generation products of early cytotoxics, such as 5- fluorouracil (5FU), are beginning to reach clinical approval.
  • Thus, substantial potential exists for additional application of IFNs and IFN inducers as anticancer therapeutics, particularly when one considers that their pleiotropic cellular and molecular effects have yet to be fully defined.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Interferon-beta / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Drug Resistance, Neoplasm. Gene Expression / drug effects. Humans. Mice. Neovascularization, Pathologic / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181052.001).
  • [ISSN] 1079-9907
  • [Journal-full-title] Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • [ISO-abbreviation] J. Interferon Cytokine Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA89544; United States / NCI NIH HHS / CA / R01 CA90914
  • [Publication-type] Lectures; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 77238-31-4 / Interferon-beta
  •  go-up   go-down


32. Kersun LS, Wimmer RS, Hoot AC, Meadows AT: Secondary malignant neoplasms of the bladder after cyclophosphamide treatment for childhood acute lymphocytic leukemia. Pediatr Blood Cancer; 2004 Mar;42(3):289-91
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary malignant neoplasms of the bladder after cyclophosphamide treatment for childhood acute lymphocytic leukemia.
  • [MeSH-major] Cyclophosphamide / adverse effects. Neoplasms, Second Primary / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Urinary Bladder Neoplasms / chemically induced
  • [MeSH-minor] Adolescent. Child. Female. Hematuria. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Neoplasm Invasiveness / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Urinary Incontinence

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14752871.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down






Advertisement